dddd
PublishedJuly 29, 2013

Is the FTC Study on Patent Trolls Going to Happen?

As we’ve noted, the FTC Chairwoman Edith Ramirez recently proposed doing a 6(b) study on the patent assertion entity business model. The proposed study has the potential to get us information about how patent trolls operate that would be nearly impossible to get without litigation.

MLex is reporting (subscription required) that FTC Commissioner Maureen Ohlhausen indicated last week after a speech at the Chamber of Commerce that she believes that a 6(b) study to examine the patent troll industry would be “appropriate.” It takes three votes to initiate the study, though.

One Commissioner who hasn’t said anything publicly about a 6(b) study on patent trolls is Commissioner Julie Brill.

Well, we may learn her views soon enough. This Wednesday (7/31), there’s a panel discussion sponsored by the American Constitution Society entitled “Patent Assertion Entities: Helping or Hurting Innovation?”

Commissioner Brill is one of the panel speakers, along with Rebecca Kelly Slaughter from Senator Schumer’s office and David Balto, a regular contributor here at Patent Progress.

I have no doubt that the subject of an FTC study will come up. If there’s news to report, we’ll let you know.

Matt Levy

Previously, Matt was patent counsel at the Computer & Communications Industry Association

More Posts

The Ripple Effects of Patent Venue

A recent article described the outsized roles that two modest cities in Texas play in U.S. patent litigation, but there's more to the story of America’s odd patent venue rules. The article alludes t...

Another startup bites the dust, courtesy of patent trolls

A handful of interest groups like to claim that patent trolls are a myth—that they're a straw man used to shape IP policy in ways that are harmful to patent holders. Mycroft AI is one of many startu...

How Challenging Low Quality Patents is Lowering Drug Prices

The FTC made headlines in May when it announced it was challenging over 300 “junk” patents in the FDA’s “Orange Book,” including patents on popular drugs like Ozempic and Victoza. With this ...

Subscribe to Patent Progress

No spam. Unsubscribe anytime.